Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
AssigneeThe Board of Trustees of the University of Arkansas System
InventorTimothy J. O'Brien
Life of this patent
Estimating the term…
Abstract
The present invention provides a transmembrane serine protease TADG-12 protein, splice variants of the TADG-12 protein and DNA fragments encoding such proteins. Also provided are vectors and host cells capable of expressing the DNAs. The present invention further provides various methods of early detection and therapies of associated ovarian and other malignancies by utilizing the DNAs and/or proteins disclosed herein.
Claims35
A DNA fragment encoding a Tumor Associated Differentially-Expressed Gene-12 (TADG-12) protein or a splicing variant of TADG-12, said DNA is selected from the group consisting of:
- (a) an isolated DNA fragment encoding a TADG-12 protein that has the amino acid sequence of SEQ ID NO. 2;
- (b) an isolated DNA fragment encoding a TADG-12 splicing variant, said variant protein has an amino acid sequence comprising part of SEQ ID NO. 2;
- and
- (c) an isolated DNA fragment differing from the isolated DNA fragments of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-12 protein or a splicing variant of TADG-12.
An isolated and purified TADG-12 protein encoded for by a DNA selected from the group consisting of:
- (a) isolated DNA encoding a TADG-12 protein that has the amino acid sequence of SEQ ID NO. 2;
- (b) isolated DNA encoding a TADG-12 splicing variant, said variant protein has an amino acid sequence comprising part of SEQ ID NO. 2;
- and
- (c) isolated DNA differing from the isolated DNA of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-12 protein or a splicing variant of TADG-12.
A method for detecting malignant hyperplasia in a biological sample, comprising the steps of:
- (a) isolating mRNA from said sample;
- and
- (b) detecting in said sample mRNA encoding a TADG-12 protein or a variant thereof, wherein the presence of said mRNA in said sample is indicative of the presence of malignant hyperplasia, wherein the absence of said mRNA in said sample is indicative of the absence of malignant hyperplasia.
A method for detecting malignant hyperplasia in a biological sample, comprising the steps of:
- (a) isolating protein from said sample;
- and
- (b) detecting in said sample a TADG-12 protein or a variant thereof, wherein the presence of said TADG-12 protein in said sample is indicative of the presence of malignant hyperplasia, wherein the absence of said TADG-12 protein in said sample is indicative of the absence of malignant hyperplasia.
A method of inhibiting expression of endogenous TADG-12 mRNA in a cell, comprising the step of:
- introducing a vector into a cell, wherein said vector comprises a DNA fragment of TADG-12 in opposite orientation operably linked to elements necessary for expression, wherein expression of said vector in said cell produces TADG-12 antisense mRNA, wherein said TADG-12 antisense mRNA hybridizes to endogenous TADG-12 mRNA, thereby inhibiting expression of endogenous TADG-12 mRNA in said cell.
A method of inhibiting expression of a TADG-12 protein in a cell, comprising the step of:
- introducing an antibody into a cell, wherein said antibody is directed against a TADG-12 protein or fragment thereof, wherein binding of said antibody to said TADG-12 protein or fragment thereof inhibits expression of said TADG-12 protein.
A method of targeted therapy to an individual, comprising the step of:
- administering a compound to an individual, wherein said compound has a targeting moiety and a therapeutic moiety, wherein said targeting moiety is specific for a TADG-12 protein.
A method of vaccinating an individual against TADG-12, comprising the step of:
- inoculating the individual with a TADG-12 protein or fragment thereof, wherein said inoculation elicits an immune response in said individual, thereby vaccinating said individual against TADG-12.
An immunogenic composition, comprising a n immunogenic fragment of a TADG-12 protein and an appropriate adjuvant.
Dependencies are inferred from the claim text.